APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

mRNA Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global mRNA Drug Market Outlook and Growth Opportunities 2026

Report ID 174014610422 December 2025198 pages

Choose your research edition.

Industry ResearchmRNA Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal mRNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global mRNA Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for mRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for mRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for mRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the mRNA Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the mRNA Drug market include Janssen, Sri Lankan Microorganisms, Pfizer, Fosun Pharma, AstraZeneca, Zydus Cadila, Moderna, CureVAC and BioNtech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global mRNA Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of mRNA Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the mRNA Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

mRNA Drug Segment by Company

Janssen

Sri Lankan Microorganisms

Pfizer

Fosun Pharma

AstraZeneca

Zydus Cadila

Moderna

CureVAC

BioNtech

mRNA Drug Segment by Type

Therapeutic Vaccine

Therapeutic Drugs

Preventive Vaccines

mRNA Drug Segment by Application

Hospital

Clinic

mRNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global mRNA Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions mRNA Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA Drug significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the mRNA Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Drug industry.

Chapter 3: Detailed analysis of mRNA Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of mRNA Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of mRNA Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA Drug Industry Trends Table 2. mRNA Drug Industry Drivers Table 3. mRNA Drug Industry Opportunities and Challenges Table 4. mRNA Drug Industry Restraints Table 5. Global mRNA Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA Drug Revenue Share by Company (2021-2026) Table 7. Global mRNA Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global mRNA Drug Sales Volume Share by Company (2021-2026) Table 9. Global mRNA Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global mRNA Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global mRNA Drug Key Company Manufacturing Base & Headquarters Table 12. Global mRNA Drug Company, Product Type & Application Table 13. Global mRNA Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global mRNA Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Therapeutic Vaccine Table 18. Significant Companies of Therapeutic Drugs Table 19. Significant Companies of Preventive Vaccines Table 20. Global mRNA Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global mRNA Drug Sales Volume by Type (2021-2026) & (k units) Table 22. Global mRNA Drug Sales Volume by Type (2027-2032) & (k units) Table 23. Global mRNA Drug Sales Volume Share by Type (2021-2026) Table 24. Global mRNA Drug Sales Volume Share by Type (2027-2032) Table 25. Global mRNA Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global mRNA Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global mRNA Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global mRNA Drug Sales Value Share by Type (2021-2026) Table 29. Global mRNA Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Global mRNA Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global mRNA Drug Sales Volume by Application (2021-2026) & (k units) Table 34. Global mRNA Drug Sales Volume by Application (2027-2032) & (k units) Table 35. Global mRNA Drug Sales Volume Share by Application (2021-2026) Table 36. Global mRNA Drug Sales Volume Share by Application (2027-2032) Table 37. Global mRNA Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global mRNA Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global mRNA Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global mRNA Drug Sales Value Share by Application (2021-2026) Table 41. Global mRNA Drug Sales Value Share by Application (2027-2032) Table 42. Global mRNA Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global mRNA Drug Sales by Region (2021-2026) & (k units) Table 44. Global mRNA Drug Sales Market Share by Region (2021-2026) Table 45. Global mRNA Drug Sales by Region (2027-2032) & (k units) Table 46. Global mRNA Drug Sales Market Share by Region (2027-2032) Table 47. Global mRNA Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global mRNA Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global mRNA Drug Sales Value Share by Region (2021-2026) Table 50. Global mRNA Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global mRNA Drug Sales Value Share by Region (2027-2032) Table 52. Global mRNA Drug Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global mRNA Drug Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global mRNA Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global mRNA Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global mRNA Drug Sales by Country (2021-2026) & (k units) Table 57. Global mRNA Drug Sales Market Share by Country (2021-2026) Table 58. Global mRNA Drug Sales by Country (2027-2032) & (k units) Table 59. Global mRNA Drug Sales Market Share by Country (2027-2032) Table 60. Global mRNA Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global mRNA Drug Sales Value Market Share by Country (2021-2026) Table 62. Global mRNA Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global mRNA Drug Sales Value Market Share by Country (2027-2032) Table 64. Janssen Company Information Table 65. Janssen Business Overview Table 66. Janssen mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Janssen mRNA Drug Product Portfolio Table 68. Janssen Recent Development Table 69. Sri Lankan Microorganisms Company Information Table 70. Sri Lankan Microorganisms Business Overview Table 71. Sri Lankan Microorganisms mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Sri Lankan Microorganisms mRNA Drug Product Portfolio Table 73. Sri Lankan Microorganisms Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Pfizer mRNA Drug Product Portfolio Table 78. Pfizer Recent Development Table 79. Fosun Pharma Company Information Table 80. Fosun Pharma Business Overview Table 81. Fosun Pharma mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Fosun Pharma mRNA Drug Product Portfolio Table 83. Fosun Pharma Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. AstraZeneca mRNA Drug Product Portfolio Table 88. AstraZeneca Recent Development Table 89. Zydus Cadila Company Information Table 90. Zydus Cadila Business Overview Table 91. Zydus Cadila mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Zydus Cadila mRNA Drug Product Portfolio Table 93. Zydus Cadila Recent Development Table 94. Moderna Company Information Table 95. Moderna Business Overview Table 96. Moderna mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Moderna mRNA Drug Product Portfolio Table 98. Moderna Recent Development Table 99. CureVAC Company Information Table 100. CureVAC Business Overview Table 101. CureVAC mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. CureVAC mRNA Drug Product Portfolio Table 103. CureVAC Recent Development Table 104. BioNtech Company Information Table 105. BioNtech Business Overview Table 106. BioNtech mRNA Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. BioNtech mRNA Drug Product Portfolio Table 108. BioNtech Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. mRNA Drug Distributors List Table 112. mRNA Drug Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. mRNA Drug Product Image Figure 2. Global mRNA Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global mRNA Drug Sales (2021-2032) & (k units) Figure 5. Global mRNA Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global mRNA Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Therapeutic Vaccine Image Figure 10. Therapeutic Drugs Image Figure 11. Preventive Vaccines Image Figure 12. Global mRNA Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global mRNA Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global mRNA Drug Sales Volume Share by Type (2021-2032) Figure 15. Global mRNA Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global mRNA Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global mRNA Drug Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Global mRNA Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global mRNA Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global mRNA Drug Sales Volume Share by Application (2021-2032) Figure 23. Global mRNA Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global mRNA Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global mRNA Drug Sales Value Share by Application (2021-2032) Figure 26. Global mRNA Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global mRNA Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global mRNA Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global mRNA Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America mRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America mRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe mRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe mRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific mRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific mRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America mRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America mRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa mRNA Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa mRNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt mRNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt mRNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt mRNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. mRNA Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. mRNA Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Therapeutic Vaccine
  • Therapeutic Drugs
  • Preventive Vaccines
Applications
  • Hospital
  • Clinic
Companies covered
  • Janssen
  • Sri Lankan Microorganisms
  • Pfizer
  • Fosun Pharma
  • AstraZeneca
  • Zydus Cadila
  • Moderna
  • CureVAC
  • BioNtech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global mRNA Drug Sales Value (2021-2032)
  4. 1.2.2 Global mRNA Drug Sales Volume (2021-2032)
  5. 1.2.3 Global mRNA Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 mRNA Drug Market Dynamics
  1. 2.1 mRNA Drug Industry Trends
  2. 2.2 mRNA Drug Industry Drivers
  3. 2.3 mRNA Drug Industry Opportunities and Challenges
  4. 2.4 mRNA Drug Industry Restraints
3 mRNA Drug Market by Company
  1. 3.1 Global mRNA Drug Company Revenue Ranking in 2025
  2. 3.2 Global mRNA Drug Revenue by Company (2021-2026)
  3. 3.3 Global mRNA Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global mRNA Drug Average Price by Company (2021-2026)
  5. 3.5 Global mRNA Drug Company Ranking (2024-2026)
  6. 3.6 Global mRNA Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global mRNA Drug Company Product Type and Application
  8. 3.8 Global mRNA Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global mRNA Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 mRNA Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 mRNA Drug Market by Type
  1. 4.1 mRNA Drug Type Introduction
  2. 4.1.1 Therapeutic Vaccine
  3. 4.1.2 Therapeutic Drugs
  4. 4.1.3 Preventive Vaccines
  5. 4.2 Global mRNA Drug Sales Volume by Type
  6. 4.2.1 Global mRNA Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global mRNA Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global mRNA Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global mRNA Drug Sales Value by Type
  10. 4.3.1 Global mRNA Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global mRNA Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global mRNA Drug Sales Value Share by Type (2021-2032)
5 mRNA Drug Market by Application
  1. 5.1 mRNA Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global mRNA Drug Sales Volume by Application
  5. 5.2.1 Global mRNA Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global mRNA Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global mRNA Drug Sales Value by Application
  9. 5.3.1 Global mRNA Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global mRNA Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global mRNA Drug Sales Value Share by Application (2021-2032)
6 mRNA Drug Regional Sales and Value Analysis
  1. 6.1 Global mRNA Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Drug Sales by Region (2021-2032)
  3. 6.2.1 Global mRNA Drug Sales by Region: 2021-2026
  4. 6.2.2 Global mRNA Drug Sales by Region (2027-2032)
  5. 6.3 Global mRNA Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global mRNA Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global mRNA Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global mRNA Drug Sales Value by Region (2027-2032)
  9. 6.5 Global mRNA Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America mRNA Drug Sales Value (2021-2032)
  12. 6.6.2 North America mRNA Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe mRNA Drug Sales Value (2021-2032)
  15. 6.7.2 Europe mRNA Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific mRNA Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific mRNA Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America mRNA Drug Sales Value (2021-2032)
  21. 6.9.2 South America mRNA Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa mRNA Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa mRNA Drug Sales Value Share by Country, 2025 VS 2032
7 mRNA Drug Country-level Sales and Value Analysis
  1. 7.1 Global mRNA Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global mRNA Drug Sales by Country (2021-2032)
  4. 7.3.1 Global mRNA Drug Sales by Country (2021-2026)
  5. 7.3.2 Global mRNA Drug Sales by Country (2027-2032)
  6. 7.4 Global mRNA Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global mRNA Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global mRNA Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA mRNA Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA mRNA Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA mRNA Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada mRNA Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada mRNA Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada mRNA Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico mRNA Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico mRNA Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico mRNA Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany mRNA Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany mRNA Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany mRNA Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France mRNA Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France mRNA Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France mRNA Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. mRNA Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. mRNA Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. mRNA Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy mRNA Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy mRNA Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy mRNA Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain mRNA Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain mRNA Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain mRNA Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia mRNA Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia mRNA Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia mRNA Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands mRNA Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands mRNA Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands mRNA Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries mRNA Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries mRNA Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries mRNA Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China mRNA Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China mRNA Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China mRNA Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan mRNA Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan mRNA Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan mRNA Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea mRNA Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea mRNA Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea mRNA Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India mRNA Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India mRNA Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India mRNA Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia mRNA Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia mRNA Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia mRNA Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia mRNA Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia mRNA Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia mRNA Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil mRNA Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil mRNA Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil mRNA Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina mRNA Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina mRNA Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina mRNA Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile mRNA Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile mRNA Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile mRNA Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia mRNA Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia mRNA Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia mRNA Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru mRNA Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru mRNA Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru mRNA Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia mRNA Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia mRNA Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia mRNA Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel mRNA Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel mRNA Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel mRNA Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE mRNA Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE mRNA Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE mRNA Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey mRNA Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey mRNA Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey mRNA Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran mRNA Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran mRNA Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran mRNA Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt mRNA Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt mRNA Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt mRNA Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen
  2. 8.1.1 Janssen Company Information
  3. 8.1.2 Janssen Business Overview
  4. 8.1.3 Janssen mRNA Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Janssen mRNA Drug Product Portfolio
  6. 8.1.5 Janssen Recent Developments
  7. 8.2 Sri Lankan Microorganisms
  8. 8.2.1 Sri Lankan Microorganisms Company Information
  9. 8.2.2 Sri Lankan Microorganisms Business Overview
  10. 8.2.3 Sri Lankan Microorganisms mRNA Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sri Lankan Microorganisms mRNA Drug Product Portfolio
  12. 8.2.5 Sri Lankan Microorganisms Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer mRNA Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer mRNA Drug Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Fosun Pharma
  20. 8.4.1 Fosun Pharma Company Information
  21. 8.4.2 Fosun Pharma Business Overview
  22. 8.4.3 Fosun Pharma mRNA Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Fosun Pharma mRNA Drug Product Portfolio
  24. 8.4.5 Fosun Pharma Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca mRNA Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca mRNA Drug Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Zydus Cadila
  32. 8.6.1 Zydus Cadila Company Information
  33. 8.6.2 Zydus Cadila Business Overview
  34. 8.6.3 Zydus Cadila mRNA Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Zydus Cadila mRNA Drug Product Portfolio
  36. 8.6.5 Zydus Cadila Recent Developments
  37. 8.7 Moderna
  38. 8.7.1 Moderna Company Information
  39. 8.7.2 Moderna Business Overview
  40. 8.7.3 Moderna mRNA Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Moderna mRNA Drug Product Portfolio
  42. 8.7.5 Moderna Recent Developments
  43. 8.8 CureVAC
  44. 8.8.1 CureVAC Company Information
  45. 8.8.2 CureVAC Business Overview
  46. 8.8.3 CureVAC mRNA Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CureVAC mRNA Drug Product Portfolio
  48. 8.8.5 CureVAC Recent Developments
  49. 8.9 BioNtech
  50. 8.9.1 BioNtech Company Information
  51. 8.9.2 BioNtech Business Overview
  52. 8.9.3 BioNtech mRNA Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 BioNtech mRNA Drug Product Portfolio
  54. 8.9.5 BioNtech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 mRNA Drug Value Chain Analysis
  2. 9.1.1 mRNA Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 mRNA Drug Sales Mode & Process
  6. 9.2 mRNA Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 mRNA Drug Distributors
  9. 9.2.3 mRNA Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst